Extended Lymphadenectomy Does Not Improve DFS or OS Among Patients with Localised Muscle Invasive Bladder Cancer By Ogkologos - November 4, 2024 1965 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SWOG S1011 study Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR Sacituzumab Govitecan Demonstrates Significant Improvement in PFS in Heavily Pretreated, Locally... September 5, 2022 Reducing Health Care Disparities Through Cancer Clinical Trials November 30, 2020 Topotecan–Berzosertib Combination Shows Promise against Small Cell Lung Cancer May 5, 2021 Atezolizumab Plus Bevacizumab Approved to Treat Liver Cancer June 4, 2020 Load more HOT NEWS FDA Approves Durvalumab in Combination with BCG for High-Risk Non-Muscle Invasive... Are New Immune-Based Treatments for Kidney and Pancreatic Cancer on the... Combination of Azacitidine and Venetoclax in Previously Untreated AML Long-Term Outcomes in Patients with Metastatic Melanoma Treated with Anti-PD1 Therapy...
